Anti-Staphylococcus aureus immunotherapy: current status and prospects

Current Opinion in Pharmacology

Volumn 9, Issue 5, 2009, Pages 552-557

  García Lara, Jorge ^a   Foster, Simon J ^b  

^a Absynth Biologics Ltd   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOXIN; ALTASTAPH; ANTIINFECTIVE AGENT; AUROGRAB; BACTERIAL POLYSACCHARIDE; BSYX A 110; COLLAGEN BINDING PROTEIN; DNA VACCINE; ENOLASE; ENTEROTOXIN; ETI 211; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN ANTIBODY; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; OXOACYL REDUCTASE; PAGIMAXIMAB; PANTON VALENTINE LEUKOCIDIN; PENTASTAPH; PEPTIDE DERIVATIVE; POLY N ACETYLGLUCOSAMINE; POLYCLONAL ANTIBODY; POLYSACCHARIDE VACCINE; PROTEIN A ANTIBODY; PROTEIN SDRD; PROTEIN SDRE; STAPHYLOCOCCUS CLUMPING FACTOR A ANTIBODY; STAPHYLOCOCCUS TOXOID; STAPHYLOCOCCUS VACCINE; SUPERANTIGEN; TEFIBAZUMAB; TOXIC SHOCK SYNDROME TOXIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 710; VANCOMYCIN; VERONATE;

ARTHRITIS; BACTERIAL CELL WALL; BACTERIAL GENETICS; BACTERIAL VIRULENCE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; DRUG TOLERABILITY; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; INFECTION RISK; INFLUENZA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; VACCINATION; VACCINE PRODUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; PATIENT SELECTION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE;

EID: 70349433674     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.07.008     Document Type: Review

References (50)

1. Peacock S.J., de Silva I., and Lowy F.D. What determines nasal carriage of Staphylococcus aureus?. Trends Microbiol 9 (2001) 605-610
2. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., and Fridkin S.K. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29 (2008) 996-1011
3. McCaig L.F., McDonald L.C., Mandal S., and Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 12 (2006) 1715-1723
4. Diederen B.M., and Kluytmans JA. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J Infect 52 (2006) 157-168
5. Projan S.J., Nesin M., and Dunman PM. Staphylococcal vaccines and immunotherapy: to dream the impossible dream?. Curr Opin Pharmacol 6 (2006) 473-479. This review and comment article provides a thought provoking update on the area, particularly in connection with the spread of community-associated methicillin-resistant S. aureus.
6. Laupland K.B., Ross T., and Gregson D.B. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis 198 (2008) 336-343
7. Klein E., Smith D.L., and Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13 (2007) 1840-1846
8. Noskin G.A., Rubin R.J., Schentag J.J., Kluytmans J., Hedblom E.C., Jacobson C., Smulders M., Gemmen E., and Bharmal M. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). Clin Infect Dis 45 (2007) 1132-1140
9. Fattom A., Schneerson R., Szu S.C., Vann W.F., Shiloach J., Karakawa W.W., and Robbins J.B. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 58 (1990) 2367-2374
10. Fattom A.I., Sarwar J., Ortiz A., and Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 64 (1996) 1659-1665
11. Lee J.C., Park J.S., Shepherd S.E., Carey V., and Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 65 (1997) 4146-4151
12. O'Riordan K., and Lee J.C. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 17 (2004) 218-234
13. Kuklin N.A., Clark D.J., Secore S., Cook J., Cope L.D., McNeely T., Noble L., Brown M.J., Zorman J.K., Wang X.M., et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74 (2006) 2215-2223. The surface protein IsdB was found on the surface of multiple S. aureus strains and vaccination with IsdB led to a specific protective response in animal models. IsdB also induces an immune response in macaques further demonstrating its potential as a vaccine component.
14. Stranger-Jones Y.K., Bae T., and Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103 (2006) 16942-16947. The authors tested a range of surface proteins as antigens and found a vaccine comprising IsdA, IsdB, SdrD and SdrE led to significant protection in invasive and lethal challenge models of infection. This highlights the requirement for a likely multivalent vaccine for protection against S. aureus.
15. Benjamin D.K., Schelonka R., White R., Holley H.P., Bifano E., Cummings J., Adcock K., Kaufman D., Puppala B., Riedel P., et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 26 (2006) 290-295
16. Rupp M.E., Holley Jr. H.P., Lutz J., Dicpinigaitis P.V., Woods C.W., Levine D.P., Veney N., and Fowler Jr. V.G. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51 (2007) 4249-4254
17. Weisman L.E. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. Arch Pediatr 14 Suppl. 1 (2007) S31-34
18. Josefsson E., Hartford O., O'Brien L., Patti J.M., and Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184 (2001) 1572-1580
19. Vernachio J.H., Bayer A.S., Ames B., Bryant D., Prater B.D., Syribeys P.J., Gorovits E.L., and Patti J.M. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 50 (2006) 511-518. Purified IgG from human donors with an elevated titre against ClfA (from S. aureus) and SdrG (from S. epidermidis) is able to protect against infection from both bacterial species in animal models. This led to the human clinical trials for Veronate in low birth weight neonates, which were unfortunately unsuccessful.
20. DeJonge M., Burchfield D., Bloom B., Duenas M., Walker W., Polak M., Jung E., Millard D., Schelonka R., Eyal F., et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151 (2007) 260-265 265.e1
21. Nanra J.S., Timofeyeva Y., Buitrago S.M., Sellman B.R., Dilts D.A., Fink P., Nunez L., Hagen M., Matsuka Y.V., Mininni T., et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 27 (2009) 3276-3280
22. Risley A.L., Loughman A., Cywes-Bentley C., Foster T.J., and Lee J.C. Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets. J Infect Dis 196 (2007) 919-927
23. Hall A.E., Domanski P.J., Patel P.R., Vernachio J.H., Syribeys P.J., Gorovits E.L., Johnson M.A., Ross J.M., Hutchins J.T., and Patti J.M. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 71 (2003) 6864-6870
24. Weems Jr. J.J., Steinberg J.P., Filler S., Baddley J.W., Corey G.R., Sampathkumar P., Winston L., John J.F., Kubin C.J., Talwani R., et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50 (2006) 2751-2755
25. Burnie J.P., Matthews R.C., Carter T., Beaulieu E., Donohoe M., Chapman C., Williamson P., and Hodgetts S.J. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 68 (2000) 3200-3209
26. Menzies B.E., and Kernodle D.S. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect Immun 64 (1996) 1839-1841
27. Bubeck Wardenburg J., Palazzolo-Ballance A.M., Otto M., Schneewind O., and DeLeo F.R. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 198 (2008) 1166-1170
28. Ragle B.E., and Bubeck Wardenburg J. Anti-Alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77 (2009) 2712-2718
29. Hu D.L., Omoe K., Sasaki S., Sashinami H., Sakuraba H., Yokomizo Y., Shinagawa K., and Nakane A. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J Infect Dis 188 (2003) 743-752
30. Verdrengh M., Kum W., Chow A., and Tarkowski A. The effect of site-specific monoclonal antibodies directed to toxic shock syndrome toxin-1 in experimental Staphylococcus aureus arthritis. Clin Exp Immunol 118 (1999) 268-270
31. Lowell G.H., Colleton C., Frost D., Kaminski R.W., Hughes M., Hatch J., Hooper C., Estep J., Pitt L., Topper M., et al. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect Immun 64 (1996) 4686-4693
32. Nilsson I.M., Verdrengh M., Ulrich R.G., Bavari S., and Tarkowski A. Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity. J Infect Dis 180 (1999) 1370-1373
33. Boyle-Vavra S., and Daum R.S. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 87 (2007) 3-9
34. Gauduchon V., Cozon G., Vandenesch F., Genestier A.L., Eyssade N., Peyrol S., Etienne J., and Lina G. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 189 (2004) 346-353
35. Brown E.L., Dumitrescu O., Thomas D., Badiou C., Koers E.M., Choudhury P., Vazquez V., Etienne J., Lina G., Vandenesch F., et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect 15 (2009) 156-164
36. Park J., Jagasia R., Kaufmann G.F., Mathison J.C., Ruiz D.I., Moss J.A., Meijler M.M., Ulevitch R.J., and Janda K.D. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 14 (2007) 1119-1127
37. Maira-Litran T., Kropec A., Goldmann D., and Pier G.B. Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide. Vaccine 22 (2004) 872-879
38. Kelly-Quintos C., Kropec A., Briggs S., Ordonez C.L., Goldmann D.A., and Pier G.B. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis 192 (2005) 2012-2019
39. Maira-Litran T., Kropec A., Goldmann D.A., and Pier G.B. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 73 (2005) 6752-6762
40. Nilsson I.M., Patti J.M., Bremell T., Hook M., and Tarkowski A. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest 101 (1998) 2640-2649
41. Clarke S.R., Brummell K.J., Horsburgh M.J., McDowell P.W., Mohamad S.A., Stapleton M.R., Acevedo J., Read R.C., Day N.P., Peacock S.J., et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 193 (2006) 1098-1108. Using human sera to probe expression libraries, a range of S. aureus antigens associated with human infection and nasal carriage were identified. IsdA was found to be required for nasal colonization in a cotton rat model and that vaccination with IsdA could prevent carriage, thus showing its potential as a human vaccine component.
42. Schaffer A.C., Solinga R.M., Cocchiaro J., Portoles M., Kiser K.B., Risley A., Randall S.M., Valtulina V., Speziale P., Walsh E., et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 74 (2006) 2145-2153
43. Glowalla E., Tosetti B., Krönke M., and Krut O. Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. Infect Immun 77 (2009) 2719-2729
44. Ferreira CS, Li J, Pincus SE, Casey LS, Mohamed N, Kreiswirth BN, Jones SM: A heteropolymer against staphylococcal protein A prevents spread of blood borne Staphylococcus aureus to target organs. In 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAACC), 2005.
45. Nagy G., Emody L., and Pal T. Strategies for the development of vaccines conferring broad-spectrum protection. Int J Med Microbiol 298 (2008) 379-395
46. Fattom A., Cho Y.H., Chu C., Fuller S., Fries L., and Naso R. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17 (1999) 126-133
47. Etz H., Minh D.B., Henics T., Dryla A., Winkler B., Triska C., Boyd A.P., Sollner J., Schmidt W., von Ahsen U., et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci U S A 99 (2002) 6573-6578
48. Ji Y., Zhang B., Van S.F., Horn, Warren P., Woodnutt G., Burnham M.K.R., and Rosenberg M. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293 (2001) 2266-2269
49. Chaudhuri R., Allen A., Owen P., Shalom G., Stone K., Harrison M., Burgis T., Lockyer M., Garcia-Lara J., Foster S., et al. Comprehensive identification of essential Staphylococcus aureus genes using Transposon-Mediated Differential Hybridisation (TMDH). BMC Genomics 10 (2009) 291-1291
50. Garmory H.S., and Titball R.W. ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect Immun 72 (2004) 6757-6763